Macroscopic Portal Vein Thrombosis in HCC Patients
Yazar
DORAN, FİGEN
ÜSKÜDAR, OĞUZ
TOKMAK, SALİH
Arslan, Burcu
BALLI, HÜSEYİN TUĞSAN
Ulku, Abdulalh
Akcam, Tolga Atilgan
Bahceci, Halil Ibrahim
Polat, Kamil Yalcin
ÖRMECİ, NECATİ
ŞİMŞEK, HALİS
Demir, Ali
ALTINTAŞ, ENGİN
DEMİR, MEHMET
YALÇIN, KENDAL
Ekinci, Nazim
Ozakyol, Aysegul Harmanci
Yucesoy, Mehmet
Uygun, Ahmet
Guerra, Vito
Delik, Anil
Kilic, Murat
Sonsuz, Abdullah
Tokat, Yaman
YILMAZ, SEZAİ
Bektas, Ahmet
AKKIZ, HİKMET
Carr, Brian I.
KURAN, SEDEF
KARAOĞULLARINDAN, ÜMİT
Üst veri
Tüm öğe kaydını gösterÖzet
Macroscopic portal vein invasion (PVT) by hepatocellular carcinoma (HCC) in the liver is one of the most important negative prognostic factors for HCC patients. The characteristics of a large cohort of such patients were examined. We found that the percent of patients with PVT significantly increased with increasing maximum tumor diameter (MTD), from 13.7% with tumors of MTD 10cm. There were similar numbers of HCC patients with very large tumors with and without PVT. Thus, MTD alone was insufficient to explain the presence of PVT, as were high AFP levels, since less than 50% of high AFP patients had PVT. However, the percent of patients with PVT was also found to significantly increase with increasing blood alpha-fetoprotein (AFP) levels and tumormultifocality. A logistic regressionmodel that included these 3 factors together showed an odds ratio of 17.9 for the combination of MTD >5.0cm plus tumor multifocality plus elevated AFP, compared to low levels of these 3 parameters. The presence or absence of macroscopic PVT may therefore represent different HCC aggressiveness phenotypes, as judged by a significant increase in tumor multifocality and AFP levels in the PVT positive patients. Factors in addition to MTD and AFP must also contribute to PVT development.
Koleksiyonlar
- Makale [92796]